

CONTENTS

Preface	v
Contributors	ix
1. Discovery of Target Molecules for Cancer Immunotherapy by Genetic and Bioinformatic Approaches	1
<i>Özlem Türeci, Thorsten Klamp, Michael Koslowski, Sebastian Kreiter, and Ugur Sahin</i>	
2. Current Strategies for the Identification of Immunogenic Epitopes of Tumor Antigens	21
<i>Ludmila Müller, Stephanie McArdle, Evelyn Derhovanessian, Thomas Flad, Ashley Knights, Robert Rees, and Graham Pawelec</i>	
3. Current and Future Role of Natural-Killer Cells in Cancer Immunotherapy	45
<i>Lisa M. Harlan and Julie Y. Djeu</i>	
4. The Role of Immune Monitoring in Evaluating Cancer Immunotherapy	59
<i>Holden T. Maecker</i>	
5. Statistical Analysis of Immune Response Assays in Cancer Immunotherapy Trials	73
<i>Susan Groshen</i>	
6. DNA Vaccines for Cancer Immunotherapy	87
<i>Heesun Kwak and Howard L. Kaufman</i>	
7. Dendritic Cells	115
<i>Weiping Zou and Tyler J. Curiel</i>	
8. Different Approaches to Dendritic Cell-Based Cancer Immunotherapy	127
<i>Noweeda Mirza and Dmitry Gabrilovich</i>	
9. Anti-Idiotypic Antibody Vaccines for the Immunotherapy of Cancer	139
<i>Malaya Bhattacharya-Chatterjee, Nitin Rohatgi, Sunil K. Chatterjee, Asim Saha, Rakesh Shukla, and Kenneth A. Foon</i>	
10. Autologous Tumor-Derived Heat Shock Protein Vaccine as a New Paradigm for Individualized Cancer Therapeutics	151
<i>Jie Dai and Zihai Li</i>	
11. Tumor-Reactive T-Cells for Adoptive Immunotherapy	167
<i>Helga Bernhard, Julia Neudorfer, Kerstin Gebhard, Heinke Conrad, Dirk H. Busch, and Christian Peschel</i>	
12. T-Cell Adoptive Immunotherapy of Cancer: <i>From Translational Models to Clinical Significance</i>	181
<i>Peter A. Cohen, Mohamed Awad, and Suyu Shu</i>	
13. Retroviral-Mediated Gene Transfer for Engineering Tumor-Reactive T-Cells	213
<i>Jeffrey J. Roszkowski and Michael I. Nishimura</i>	

14.	Harnessing the Potential of Graft-vs-Tumor	235
	<i>Nancy M. Hardy and Michael R. Bishop</i>	
15.	Tumor-Induced Immune Suppression and Immune Escape: <i>Mechanisms and Impact on the Outcome of Immunotherapy of Malignant Disease</i>	263
	<i>Michael Campoli and Soldano Ferrone</i>	
16.	The Tumor Microenvironment: <i>Regulation of Antitumor Immunity and Implications for Immunotherapy</i>	285
	<i>George Coukos and Jose-Ramon Conejo-Garcia</i>	
17.	Manipulation of Lymphocyte Homeostasis for Enhancing Antitumor Immunity	303
	<i>Eduardo Davila and Esteban Celis</i>	
18.	Fast-Lane Evolution in the Tumor Microenvironment	317
	<i>Gabriella Marincola and Francesco M. Marincola</i>	
19.	Manipulating Immunological Checkpoints to Maximize Antitumor Immunity	331
	<i>Leisha A. Emens, R. Todd Reilly, and Elizabeth M. Jaffee</i>	
20.	Interleukin-2 as Cancer Therapy	355
	<i>Joseph I. Clark and Kim A. Margolin</i>	
21.	Biological and Clinical Properties of the Type 1 Interferons	365
	<i>Douglas W. Leaman, Shaun Rosebeck, and Ernest C. Borden</i>	
22.	Promising γ -Chain Cytokines for Cancer Immunotherapy: <i>Interleukins-7, -15, and -21 as Vaccine Adjuvants, Growth Factors and Immunorestoratives</i>	397
	<i>Terry J. Fry and Crystal L. Mackall</i>	
23.	The Therapeutic Use of Natural-Killer Cells in Hematological Malignancies	415
	<i>Sherif S. Farag and Michael A. Caligiuri</i>	
24.	Antibody Therapy for Solid Tumors	433
	<i>Cristina I. Truica, Dorinda Rouch, and Carlos L. Arteaga</i>	
25.	Antibody Therapy for Non-Hodgkin's Lymphoma	445
	<i>Stephen M. Ansell and Thomas E. Witzig</i>	
26.	Approaches to In Vivo Imaging of Cancer Immunotherapy	457
	<i>George A. Vielhauer, Bond Almand, Mary L. Disis, David A. Mankoff, and Keith L. Knutson</i>	
27.	Design Issues for Early-Stage Clinical Trials for Cancer Vaccines	479
	<i>Gina R. Petroni</i>	
28.	Monoclonal Antibody Therapy of Cancer	487
	<i>Hossein Borghaei, Matthew K. Robinson, and Louis M. Weiner</i>	
	Index	503



<http://www.springer.com/978-1-58829-564-4>

Immunotherapy of Cancer

Disis, M.L. (Ed.)

2006, XII, 516 p. 52 illus., Hardcover

ISBN: 978-1-58829-564-4

A product of Humana Press